A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas (INTERCEPT-H3)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04808245 |
|
Recruitment Status :
Recruiting
First Posted : March 22, 2021
Last Update Posted : April 5, 2024
|
Sponsor:
German Cancer Research Center
Collaborators:
Johannes Gutenberg University Mainz
Charite University, Berlin, Germany
Roche Pharma AG
German Cancer Aid
Information provided by (Responsible Party):
German Cancer Research Center
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | March 2025 |
| Estimated Study Completion Date : | March 2025 |